Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Blinded, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Cell Therapy Based With Artificially Expanded CD4+CD25+CD127- Regulatory Lymphocytes and Anti-CD20 Antibody in Pediatric Patients With Presymptomatic Diabetes Type 1 (Stage 1)

NCT06688331 is registered in ClinicalTrials.gov with PolTREG S.A. as lead sponsor.

NCT NCT06688331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06688331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Blinded, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Cell Therapy Based With Artificially Expanded CD4+CD25+CD127- Regulatory Lymphocytes and Anti-CD20 Antibody in Pediatric Patients With Presymptomatic Diabetes Type 1 (Stage 1)
Lead sponsor
PolTREG S.A.
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
December 31, 2032
Enrollment
150 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, diabetes mellitus, type i, presymptomatic diabetes type 1 (stage 1)